[其他] 何晶 臉書

The Japanese Daiichi Sankyo has announced that they are preparing to go into Phase 1 trials for their mRNA vaccine sometime in late March.

Over in China, there are a handful of companies also working on mRNA vaccines, though they are probably further behind.

Some of the bigger drug makers in China are buying minority stakes in some of these younger start-ups.

However, while the science is known, it requires various building blocks to develop a vaccine.

For mRNA, for example, one key technology is the ability to produce the right type of fatty lipids to protect the mRNA, and also serve a dual purpose of stimulating the deeper and more complex immune response such as trhe production of T cells and neutralising antibodies.

https://bit.ly/3vgDBCg

日本第一三共公司將在3月底

進行一期的mRNA疫苗試驗

在中國也有公司在做mRNA疫苗

只是進度比較後面

一些中國的大公司正在買年輕公司的股份

然而，在科學上，需要各種成分研發疫苗

例如mRNA疫苗

關鍵科技是生產正確的脂肪來保護RNA

還有更複雜的免疫反應

例如T細胞的產生及中和抗體

所以何晶接下來會投資

正在研發mRNA疫苗的公司嗎

她的眼光不是一項很好嗎！！！

未來會有更多mRNA疫苗！！！

--